TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31370191

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 87

Group type: COMPARATOR
Intervention: Self-help brochure (control)
Number of subjects: 87
Study: 28187918

Group type: EXPERIMENTAL
Intervention: naproxen+diazepam
Number of subjects: 114

Group type: COMPARATOR
Intervention: naproxen+placebo
Number of subjects: 114
Study: 26113445

Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wake
Number of subjects: 0
Study: 22997048

Group type: EXPERIMENTAL
Intervention: Generous grading by professors
Number of subjects: 3

Group type: COMPARATOR
Intervention: Frugal grading by professors
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Poor feedback
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Positive grade/feedback condition
Number of subjects: 3
Study: 22023735

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate and high calorie oral nutritional supplement
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo medication and low calorie oral nutritional supplementation
Number of subjects: 200
Study: 19628319

Group type: EXPERIMENTAL
Intervention: High-dose B vitamin capsule (40 mg of folic acid, 100 mg of vitamin B6, and 2 mg of vitamin B12)
Number of subjects: 659

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 659
Study: 16733228

Group type: EXPERIMENTAL
Intervention: Doxazosin (1 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 14998605

Group type: EXPERIMENTAL
Intervention: Declined entry into randomised clinical trials of adjuvant cancer therapy
Number of subjects: 22
Study: 11150899

Group type: EXPERIMENTAL
Intervention: 2.5 mg diazepam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 12
Study: 9385303

Group type: EXPERIMENTAL
Intervention: Computerized display of charges for clinical laboratory tests
Number of subjects: 12271

Group type: EXPERIMENTAL
Intervention: Computerized display of charges for radiological tests
Number of subjects: 12271

Group type: COMPARATOR
Intervention: Historical controls for clinical laboratory tests
Number of subjects: 12271
Study: 7881586

Group type: EXPERIMENTAL
Intervention: Hémovigilance system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cohort studies on post‐transfusion hepatitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized study on cytomegalovirus infections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hémovigilance in the context of epidemics and new hazards
Number of subjects: 0
Study: 3291533

Group type: EXPERIMENTAL
Intervention: Vacuum aspiration under general anesthesia
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Prostaglandin (16,16 dimethyltrans‐delta 2PGE1 methyl ester in pessary form)
Number of subjects: 32
Study: 30924381

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) for 12 months
Number of subjects: 144

Group type: COMPARATOR
Intervention: Radical prostatectomy (control group)
Number of subjects: 144
Study: 29878225

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 2862

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 2862

Group type: EXPERIMENTAL
Intervention: Trastuzumab→Lapatinib
Number of subjects: 2862

Group type: EXPERIMENTAL
Intervention: Trastuzumab+Lapatinib
Number of subjects: 2862

Group type: COMPARATOR
Intervention: No TRA
Number of subjects: 2862
Study: 28535396

Group type: EXPERIMENTAL
Intervention: Adenovirus detection in conjunctival samples
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Enterovirus 70 detection in conjunctival samples
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Enterovirus 71 detection in conjunctival samples
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Coxsackievirus A16 detection in conjunctival samples
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Coxsackievirus A24 detection in conjunctival samples
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Adenovirus detection in pharyngeal samples
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Enterovirus 70 detection in pharyngeal samples
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Enterovirus 71 detection in pharyngeal samples
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Coxsackievirus A16 detection in pharyngeal samples
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Coxsackievirus A24 detection in pharyngeal samples
Number of subjects: 62
Study: 26208378

Group type: EXPERIMENTAL
Intervention: Aspirin pretreatment
Number of subjects: 236

Group type: COMPARATOR
Intervention: No aspirin pretreatment
Number of subjects: 236
Study: 23756308

Group type: EXPERIMENTAL
Intervention: Psychoeducational videotaped message (autonomy-supportive)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Brochure (neutral message)
Number of subjects: 415
Study: 21354028

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 19881436

Group type: EXPERIMENTAL
Intervention: Case-based (CB) questions
Number of subjects: 130

Group type: COMPARATOR
Intervention: Non-case-based (non-CB) questions
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Pretest
Number of subjects: 130
Study: 17542110

Group type: EXPERIMENTAL
Intervention: Micronutrient supplement containing vitamin A, vitamin B2, vitamin B6, vitamin B12, folic acid, niacin, calcium pantothenate, vitamin C, vitamin E, iron, lysine, and calcium, daily for 9 months
Number of subjects: 413

Group type: COMPARATOR
Intervention: Control group with no nutritional intervention
Number of subjects: 413
Study: 12594004

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 50 mg denaverine hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of 50 mg denaverine hydrochloride in aqueous solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rectal administration of 50 mg denaverine hydrochloride in aqueous solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suppository formulation of 50 mg denaverine hydrochloride
Number of subjects: 0
Study: 10632281

Group type: EXPERIMENTAL
Intervention: Nurse Practitioners
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Physicians
Number of subjects: 1316
Study: 9360031

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (30 min, 3-4 times weekly for 6 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (standard rehabilitation program)
Number of subjects: 41
Study: 1551298

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine hydrochloride 25 mg p.o. four times a day (total, 10 doses)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3838406

Group type: EXPERIMENTAL
Intervention: 0.4 mg of SIN-1
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30861550

Group type: EXPERIMENTAL
Intervention: Prophylactic dose apixaban
Number of subjects: 500

Group type: COMPARATOR
Intervention: No anticoagulation (standard of care)
Number of subjects: 500
Study: 30202851

Group type: EXPERIMENTAL
Intervention: DZX + placebo (DZX + PL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DZX + metformin (DZX + MTF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Double placebo (PL + PL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DZX treatment
Number of subjects: 12
Study: 27377085

Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Burch colposuspension
Number of subjects: 81
Study: 24811940

Group type: EXPERIMENTAL
Intervention: Tidal volume ≤6 ml/kg PBW
Number of subjects: 2184

Group type: COMPARATOR
Intervention: Tidal volume ≥10 ml/kg PBW
Number of subjects: 2184

Group type: EXPERIMENTAL
Intervention: Sedation needs (propofol and midazolam)
Number of subjects: 2184
Study: 20670085

Group type: EXPERIMENTAL
Intervention: FDR gemcitabine (1,000 mg/m² on days 1 and 15), oxaliplatin (60 mg/m² on days 1 and 15), capecitabine (1,000 mg/m² BID on days 1-7 and 15-21)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: FDR gemcitabine, oxaliplatin, and capecitabine regimen
Number of subjects: 77
Study: 19440076

Group type: EXPERIMENTAL
Intervention: Nicotine administered by cigarette smoking
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4 mg of nicotine gum
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 40
Study: 17342790

Group type: EXPERIMENTAL
Intervention: Lavender inhalation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sunflower inhalation
Number of subjects: 70
Study: 15041620

Group type: EXPERIMENTAL
Intervention: Tramadol 40 mg (Group T(40))
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg (Group T(100))
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tramadol 200 mg (Group T(200))
Number of subjects: 100

Group type: COMPARATOR
Intervention: Isotonic sodium chloride (Group P)
Number of subjects: 100
Study: 11352774

Group type: EXPERIMENTAL
Intervention: Lexipafant (10 mg) administered intravenously over 5 min
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo administered intravenously over 5 min
Number of subjects: 71
Study: 9223077

Group type: EXPERIMENTAL
Intervention: Global motion coherence thresholds test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visuo-manual accuracy in posting a card through a slot
Number of subjects: 0
Study: 8491237

Group type: EXPERIMENTAL
Intervention: Ambroxol 250 mg b.d.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ambroxol 500 mg b.d.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 2955964

Group type: EXPERIMENTAL
Intervention: Nicotinamide
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 607511

Group type: EXPERIMENTAL
Intervention: Cyclic somatostatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 31812327

Group type: EXPERIMENTAL
Intervention: Four-session intervention alongside treatment-as-usual (TAU)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)-only
Number of subjects: 34
Study: 30616601

Group type: EXPERIMENTAL
Intervention: PSMA PET/CT scan prior to SRT planning (n = 103)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Standard SRT (control arm 1, n = 90)
Number of subjects: 193
Study: 28960818

Group type: EXPERIMENTAL
Intervention: Stand-alone interbody spacer at C4–C5 and C5–C6
Number of subjects: 11

Group type: COMPARATOR
Intervention: Two-level locking static plate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Rotational-dynamic plate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Comparison of two plating systems (locking static plate vs rotational-dynamic plate)
Number of subjects: 11
Study: 26013300

Group type: EXPERIMENTAL
Intervention: Hemoglobin transfusion threshold of 70 g/L
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hemoglobin transfusion threshold of 90 g/L
Number of subjects: 0
Study: 23374004

Group type: EXPERIMENTAL
Intervention: 153Sm isotope monotherapy
Number of subjects: 177

Group type: COMPARATOR
Intervention: Combined therapy (153Sm + EBRT)
Number of subjects: 177
Study: 21060997

Group type: EXPERIMENTAL
Intervention: Pre-quit reaction times on a computerized modified Simon task (10-h nicotine-deprived vs. not deprived)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Viewing positive and smoking slides
Number of subjects: 365

Group type: COMPARATOR
Intervention: Viewing negative slides
Number of subjects: 365
Study: 19873913

Group type: EXPERIMENTAL
Intervention: Eye acupuncture combined with oral administration of compound Danshen tablets
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral administration of compound Danshen tablets
Number of subjects: 60
Study: 16835737

Group type: EXPERIMENTAL
Intervention: Steroids/local anaesthetics
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline/local anaesthetic
Number of subjects: 40
Study: 15213584

Group type: EXPERIMENTAL
Intervention: Methylphenidate plus psychosocial treatment (parent training, counseling, social skills training, academic assistance, psychotherapy)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Methylphenidate alone
Number of subjects: 103

Group type: COMPARATOR
Intervention: Methylphenidate plus attention control treatment
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: All treatments (including methylphenidate alone and with psychosocial treatment)
Number of subjects: 103
Study: 11555194

Group type: EXPERIMENTAL
Intervention: IFN + Zn (Interferon with polaprezinc)
Number of subjects: 75

Group type: COMPARATOR
Intervention: IFN alone
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: IFN + Zn
Number of subjects: 75
Study: 10209404

Group type: EXPERIMENTAL
Intervention: Hand-held Doppler (HHD) assessment
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tourniquet testing
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Selective duplex scanning
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Selective criteria for duplex scanning
Number of subjects: 72
Study: 7949546

Group type: EXPERIMENTAL
Intervention: Intravesical ureteroneocystostomy (LP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extravesical ureteroneocystostomy (Lich)
Number of subjects: 0
Study: 3239469

Group type: EXPERIMENTAL
Intervention: Nicotine Cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine Free Cigarettes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deprived
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondeprived
Number of subjects: 0
Study: 31899383

Group type: EXPERIMENTAL
Intervention: Clinical Nursing Practice Guideline (CNPG) of Enteral Nutrition (EN) care
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard nursing care
Number of subjects: 44
Study: 30211929

Group type: EXPERIMENTAL
Intervention: Transendocardial injection of autologous bone marrow-derived CD133+ stem cells
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 28183323

Group type: EXPERIMENTAL
Intervention: ICT intervention with home monitoring kit including home-leaving sensors, smoke and water leak sensors, bed sensors, and automatic lights
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 320
Study: 25594550

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH) levels above the upper limit of normal (65 pg/mL)
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: PTH levels (per 10 units increase)
Number of subjects: 1840

Group type: EXPERIMENTAL
Intervention: PTH levels
Number of subjects: 1840
Study: 24244450

Group type: EXPERIMENTAL
Intervention: Keypress turning words ON
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Keypress turning words OFF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Keypress with aversive tone ON/OFF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variable association between responses and effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affective response effects assessing implicit in-group favoritism
Number of subjects: 0
Study: 20838324

Group type: EXPERIMENTAL
Intervention: FAM regimen (5‐fluorouracil 600 mg/m(2) IV drip on days 1, 8, 29, and 36; doxorubicin 30 mg/m(2) IV bolus injection on days 1 and 29; mitomycin‐C 10 mg/m(2) IV bolus injection on day 1; repeated every 8 weeks)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: FOLFOX regimen (oxaliplatin 100 mg/m(2) IV drip on days 1 and 15; leucovorin 400 mg/m(2) IV drip on days 1 and 15; 5‐FU 400 mg/m(2) IV bolus injection; 5‐FU 2.4/3.0 mg/m(2) continuous IV infusion for 48 hours on day 1, 2, 15, and 16; repeated every 4 weeks for at least 4 cycles)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Postoperative chemotherapy (FAM and FOLFOX regimens combined)
Number of subjects: 268
Study: 18307374

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (twice-daily dosing)
Number of subjects: 1009
Study: 17075373

Group type: EXPERIMENTAL
Intervention: 5 ppm inhaled nitric oxide
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo gas
Number of subjects: 385
Study: 15514886

Group type: EXPERIMENTAL
Intervention: Bioglass used in group B (14 cases)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Autogenous iliac cancellous bone in group A (25 cases)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Comparison between group A and group B
Number of subjects: 39

Group type: COMPARATOR
Intervention: Comparison between complete and incomplete alveolar cleft in both groups
Number of subjects: 39
Study: 11346212

Group type: EXPERIMENTAL
Intervention: Pre-cystic artery TAE (Group 1, 20 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Post-cystic artery TAE (Group 2, 20 patients)
Number of subjects: 40
Study: 9237711

Group type: EXPERIMENTAL
Intervention: Pn‐CRM197 vaccines (5 microg)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Pn‐CRM197 vaccines (2 microg)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Pn‐CRM197 vaccines (0.5 microg)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: PS formulations
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: PS vaccines (5 microg)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Pn‐CRM197 vaccines
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: HbOC vaccine with Pn‐CRM197
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 400
Study: 8218691

Group type: EXPERIMENTAL
Intervention: Calcium mupirocin ointment (n = 170)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo ointment (n = 169)
Number of subjects: 339
Study: 3550021

Group type: COMPARATOR
Intervention: PRP vaccine
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: PRP-D vaccine
Number of subjects: 585
Study: 29292114

Group type: EXPERIMENTAL
Intervention: Iliac vein stenting
Number of subjects: 58

Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 58
Study: 27855100

Group type: EXPERIMENTAL
Intervention: Online 'LARC First' training and rapid referral pathways
Number of subjects: 729

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 729
Study: 24323641

Group type: EXPERIMENTAL
Intervention: safinamide 100 mg/day
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: safinamide 50 mg/day
Number of subjects: 669

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 669
Study: 23466078

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 795

Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 795
Study: 20589977

Group type: COMPARATOR
Intervention: Continued absence of LVH
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Regression of LVH
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Persistent LVH
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: New ECG LVH
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: New LVH
Number of subjects: 663
Study: 18004283

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 16677528

Group type: EXPERIMENTAL
Intervention: itraconazole 200 mg Bid
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: itraconazole 200 mg qd
Number of subjects: 21
Study: 12882842

Group type: EXPERIMENTAL
Intervention: Insulin 70/30 mix plus metformin
Number of subjects: 188

Group type: COMPARATOR
Intervention: Triple oral therapy
Number of subjects: 188
Study: 10827161

Group type: EXPERIMENTAL
Intervention: Combination of interferon‐alfa (6 MU subcutaneously 3 times weekly for 6 months followed by 3 MU for 6 months) and ribavirin (for 4, 6, or 12 months) in group C (n=129)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Interferon‐alfa alone (12‐month course with high initial doses) in group A (n=95)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Interferon‐alfa alone (10 MU for 3 months followed by 6 MU for 3 months, followed by 3 MU for 6 months) in group B (n=83)
Number of subjects: 307
Study: 8853768

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 800 mg b.d. plus antibiotics (amoxycillin, metronidazole, clarithromycin, cefuroxime axetil, tetracycline, tetracycline plus metronidazole, or clarithromycin plus tetracycline) for 14 days
Number of subjects: 100
Study: 1477191

Group type: EXPERIMENTAL
Intervention: MDE (140 mg)
Number of subjects: 6
Study: 6505888

Group type: EXPERIMENTAL
Intervention: Controlled physical exercise in reduced environmental lighting (54 lux)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled physical exercise in normal lighting (320 lux)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled physical exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled exercise (step-climbing) for 30 minutes
Number of subjects: 0
Study: 30675515

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus nonsteroidal aromatase inhibitor (AI)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo plus nonsteroidal aromatase inhibitor (AI)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus nonsteroidal AI
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo plus nonsteroidal AI
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Abemaciclib
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study: 29121545

Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Wait-Listed Control (WLC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Exercise-Training Active Control (AC)
Number of subjects: 41
Study: 27578807

Group type: EXPERIMENTAL
Intervention: Culotte stenting
Number of subjects: 300

Group type: COMPARATOR
Intervention: TAP stenting
Number of subjects: 300
Study: 24603217

Group type: EXPERIMENTAL
Intervention: Moderate dose statin (atorvastatin 10 mg/d or equivalent, n=675)
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: Intensive dose statin (atorvastatin 20 or 40 mg/d or equivalent, n=680)
Number of subjects: 1355

Group type: COMPARATOR
Intervention: Moderate dose statin
Number of subjects: 1355

Group type: COMPARATOR
Intervention: Intensive dose statin
Number of subjects: 1355

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 1355
Study: 22066819

Group type: EXPERIMENTAL
Intervention: Dark chocolate (40 g, cocoa > 85%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Milk chocolate (cocoa < 35%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Catechin (0.1-10 μm)
Number of subjects: 40